Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.
The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.
Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.
One-Day TMS condenses transcranial magnetic stimulation therapy treatment from a daily month-long process to 1 day, with rapid and durable results, NeuroStim says.
The risk for MDD is greatest in the first month after diagnosis and the absolute risk remains elevated even 20 years later, making early detection and treatment imperative.